Efficacy of Latanoks (latanaprost 0.005%) in patients with open-angle glaucoma
DOI:
https://doi.org/10.31288/oftalmolzh201556871Keywords:
glaucoma, tonometry, visual field, intraocular pressureAbstract
Introduction: Glaucoma refers to chronic diseases that require constant treatment. Conservative treatment of glaucoma involves the continuous assigning of local hypotensive medications for a long time to maintain normal range of intraocular pressure (IOP).
Objective: To examine the efficacy of Latanoks medication in clinical practice with patients having primary open-angle glaucoma.
Material and methods: 20 patients (30 eyes) have been under the observation with primary open-angle glaucoma stage I-III. All the patients were transferred to Latanoks monotherapy due to the lack of the intraocular pressure compensation. Tonometry, tonography, electronic static perimetry were performed at the beginning and the end of the observation period.
Results: The use of Latanoks medication for the treatment of patients with an open-angle glaucoma within three months has led to a decrease of tonography Po index from an average (20.0 ± 6.0) mm Hg to (14.9 ± 3.0) mm Hg (p < 0.0003). The use of Latanoks for the treatment of patients with open-angle glaucoma within three months has led to a decrease of IOP (by Maklakov) from an average (22.8 ± 5.0) mm Hg. to (17.6 ± 2.0) mm Hg (p < 0.0002) and also has allowed to keep the visual field indicators stable for three months.
Conclusion: Latanoks is an effective hypotensive medication that does authentically lower IOP and helps to save the visual field.
References
1.Egorov EA. [Hypotensive treatment of glaucoma]. Klinicheskaya oftalmologiya. 2000; 1: 6-10. In Russian.
2.Egorov EA, Romanova OV. [Perspectives of latanoprost prostaglandin F2 Alpha analogue in hypertensive glaucoma therapy]. Vest oftalmol. 1998; 114 (4): 19-20. In Russian.
3.Erichev VP. [Main directions of hypotensive treatment of patients with primary glaucoma]. Rus. oftalm. zhur. 2000; 1(1): 18-21. In Russian.
4.Nesterov AP. [General glaucoma treatment methods evaluation and selection]. Fiziologia i patologiya vnutriglaznogo davleniya. 1987; 60-68. In Russian.
5.European Glaucoma Society Terminology & Guidelines for Glaucoma (European Directive). Glaucoma Society. 2nd ed. Savona Italy: DOGMA Editrice. 2003; 3 (R): 3-26.
6.Aoyama Y. Effect of UF-021 (Rescula (r)), a prostaglandin-related compound on intraocular pressure and anterior chamber flare counts (in Japanese). Ueno s. Folia. Ophthalmol. J. 1996; 47: 914-919.
7.Aquino MV, Lat-Luna M. The effect of latanoprost vs timolol on intraocular pressure in patients with glaucoma and ocular hypertension. Asian j. Ophthalmol. 1999; 1(R): 3-7. https://doi.org/10.35119/asjoo.v1i3.295
8.Azuma I, Masuda K, Kitazawa Y. et al. Double-masked comparative study of UF-021 and timolol ophthalmic solutions in patients with primary open-angle glaucoma or ocular hypertension. Jpn. J. Ophthalmol. 1993; 37(4): 514-525.
9.Cardascia N, Vetrugno M, Trabucco T, Cantatore F, Sborgia C. Effects of travoprost eye drops on intraocular pressure and pulsatile ocular blood flow: a 180-day, randomized, double-masked comparison with latanoprost eye drops in patients with open-angle glaucoma. Current Therapeutic Research: Clinical and Experimental. 2003; 63: 389-400. https://doi.org/10.1016/S0011-393X(03)00112-7
10.Chew PT, Hung PT, Aung T. Efficacy of latanoprost in reducing intraocular pressure in patients with primary angle-closure glaucoma. Surv. Ophthalmol. 2002; 47(1): 125-128. https://doi.org/10.1016/S0039-6257(02)00305-3
11.David R. Changing Therapeutic paradigms in glaucoma management. Expert. Opin. Investing drugs.1998; 7:1063-1086. https://doi.org/10.1517/13543784.7.7.1063
12.Diestelhorst M, Nordmann JP, Toris CB. Combined therapy of pilocarpine or latanoprost with timolol versus latanoprost monotherapy. Surv. Ophthalmol. 2002; 47(1): 155-161. https://doi.org/10.1016/S0039-6257(02)00329-6
13.Dubiner HB, Sircy MD, Landry T, Bergamini MV. W, Silver LH, Turner FD, Robertson S, Andrew RM, Weiner A, Przydryga J. Comparison of the diurnal ocular hypotensive efficacy of travoprost and latanoprost over a 44-hour period in patients with elevated intraocular pressure. Clinical Therapeutics. 2004.; 26: 84-91. https://doi.org/10.1016/S0149-2918(04)90008-2
14.Easthope SE. Topical bimatoprost: a review of its use in open-angle glaucoma and ocular Hypertension. Perry CM. Drugs Aging. 2002; 19: 231-248. https://doi.org/10.2165/00002512-200219030-00008
15.Fellman RL, Sullivan EK, Ratliff M. et al. Comparison of travoprost 0.0015% and 0.004% with timolol 0.5% in patients with elevated IOP: a six- month, masked, multicenter trial. Ophthalmology. 2002; 109: 998-1008. https://doi.org/10.1016/S0161-6420(02)01010-2
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 С. В. Шамбра, А. Р. Король
This work is licensed under a Creative Commons Attribution 4.0 International License.
This work is licensed under a Creative Commons Attribution 4.0 International (CC BY 4.0) that allows users to read, download, copy, distribute, print, search, or link to the full texts of the articles, or use them for any other lawful purpose, without asking prior permission from the publisher or the author as long as they cite the source.
COPYRIGHT NOTICE
Authors who publish in this journal agree to the following terms:
- Authors hold copyright immediately after publication of their works and retain publishing rights without any restrictions.
- The copyright commencement date complies the publication date of the issue, where the article is included in.
DEPOSIT POLICY
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) during the editorial process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work with an acknowledgement of its initial publication in this journal.
- Post-print (post-refereeing manuscript version) and publisher's PDF-version self-archiving is allowed.
- Archiving the pre-print (pre-refereeing manuscript version) not allowed.
